Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of$ 0.14. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -7.14%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.15 per share when it actually produced a loss of $0.05, delivering a surprise of 66.67%.Over the last four quarters, ...